Neuropharm shares plummet as lead candidate fails autism Phase III trial
This article was originally published in Scrip
Executive Summary
Neuropharm's lead candidate, NPL-2008, a formulation of the SSRI antidepressant fluoxetine, has failed to meet the primary endpoint of reducing repetitive behaviour in autism in the Phase III SOFIA study, sending its shares down by 83% to close at £0.17 on February 18th on the London Stock Exchange.